888 related articles for article (PubMed ID: 18050222)
1. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
2. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.
Teng YK; Levarht EW; Toes RE; Huizinga TW; van Laar JM
Ann Rheum Dis; 2009 Jun; 68(6):1011-6. PubMed ID: 18647852
[TBL] [Abstract][Full Text] [Related]
3. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.
Vos K; Thurlings RM; Wijbrandts CA; van Schaardenburg D; Gerlag DM; Tak PP
Arthritis Rheum; 2007 Mar; 56(3):772-8. PubMed ID: 17328049
[TBL] [Abstract][Full Text] [Related]
4. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.
Cambridge G; Leandro MJ; Edwards JC; Ehrenstein MR; Salden M; Bodman-Smith M; Webster AD
Arthritis Rheum; 2003 Aug; 48(8):2146-54. PubMed ID: 12905467
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy.
Leandro MJ; Cooper N; Cambridge G; Ehrenstein MR; Edwards JC
Rheumatology (Oxford); 2007 Jan; 46(1):29-36. PubMed ID: 16735454
[TBL] [Abstract][Full Text] [Related]
6. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.
Roll P; Palanichamy A; Kneitz C; Dorner T; Tony HP
Arthritis Rheum; 2006 Aug; 54(8):2377-86. PubMed ID: 16869000
[TBL] [Abstract][Full Text] [Related]
7. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
[TBL] [Abstract][Full Text] [Related]
8. Detection, identification and in vivo treatment responsiveness of bone morphogenetic protein (BMP)-activated cell populations in the synovium of patients with rheumatoid arthritis.
Verschueren PC; Lories RJ; Daans M; Théate I; Durez P; Westhovens R; Luyten FP
Ann Rheum Dis; 2009 Jan; 68(1):117-23. PubMed ID: 18276742
[TBL] [Abstract][Full Text] [Related]
9. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.
Leandro MJ; Cambridge G; Ehrenstein MR; Edwards JC
Arthritis Rheum; 2006 Feb; 54(2):613-20. PubMed ID: 16447239
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of rheumatoid factor-producing B cells from the synovial fluid of rheumatoid arthritis patients.
Reparon-Schuijt CC; van Esch WJ; van Kooten C; Levarht EW; Breedveld FC; Verweij CL
Arthritis Rheum; 1998 Dec; 41(12):2211-20. PubMed ID: 9870878
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
Bokarewa M; Lindholm C; Zendjanchi K; Nadali M; Tarkowski A
Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys.
Schröder C; Azimzadeh AM; Wu G; Price JO; Atkinson JB; Pierson RN
Transpl Immunol; 2003; 12(1):19-28. PubMed ID: 14551029
[TBL] [Abstract][Full Text] [Related]
13. CD95-Mediated control of anti-citrullinated protein/peptides antibodies (ACPA)-producing plasma cells occurring in rheumatoid arthritis inflamed joints.
Rodríguez-Bayona B; Pérez-Venegas JJ; Rodríguez C; Brieva JA
Rheumatology (Oxford); 2007 Apr; 46(4):612-6. PubMed ID: 17132692
[TBL] [Abstract][Full Text] [Related]
14. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.
Popa C; Leandro MJ; Cambridge G; Edwards JC
Rheumatology (Oxford); 2007 Apr; 46(4):626-30. PubMed ID: 17189244
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
[TBL] [Abstract][Full Text] [Related]
16. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
[TBL] [Abstract][Full Text] [Related]
17. Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype.
Thurlings RM; Wijbrandts CA; Mebius RE; Cantaert T; Dinant HJ; van der Pouw-Kraan TC; Verweij CL; Baeten D; Tak PP
Arthritis Rheum; 2008 Jun; 58(6):1582-9. PubMed ID: 18512774
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects.
Quartuccio L; Lombardi S; Fabris M; Masolini P; Saracco M; Pellerito R; De Vita S
Ann N Y Acad Sci; 2009 Sep; 1173():692-700. PubMed ID: 19758217
[TBL] [Abstract][Full Text] [Related]
19. Alterations of the synovial T cell repertoire in anti-citrullinated protein antibody-positive rheumatoid arthritis.
Cantaert T; Brouard S; Thurlings RM; Pallier A; Salinas GF; Braud C; Klarenbeek PL; de Vries N; Zhang Y; Soulillou JP; Tak PP; Baeten D
Arthritis Rheum; 2009 Jul; 60(7):1944-56. PubMed ID: 19565497
[TBL] [Abstract][Full Text] [Related]
20. [B cell depletion therapy using anti-CD20 antibodies in rheumatoid arthritis].
Yukawa N; Mimori T
Clin Calcium; 2007 Apr; 17(4):569-76. PubMed ID: 17404487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
